Over the past several months I have received inquiries asking about nicotine as a treatment for Parkinsons. Do I recommend this option out of the over 120 natural options I have determined help reverse Parkinson’s symptoms? Early studies agreed that nicotine is a predictor for a diagnosis of Parkinsons.

The predictive studies use a large data base to ask respondents a number of questions about their dietary and lifestyle habits. Researchers then follow up with respondents after many years – often one or two decades later. These predictive (or sometimes called epidemiological) studies find that smoking does predict whether a person is eventually diagnosed with Parkinsons.

Clinical studies are a very different approach to designing a study. These studies typically select a sample of persons with Parkinsons, then divide the group into an experimental group and a control group. The experimental group uses nicotine patches. The control group gets a patch without the infusion of nicotine.

What do these studies find? The meta analysis below (which is a systematic review of all clinical nicotine studies) does not recommend the use of nicotine patches as a treatment for Parkinsons. Of course smoking is also not recommended

Do I now recommend that you begin using nicotine patches with the anticipation it offers relief from Parkinson’s symptoms? I do know some medical professionals recommend this option.

Given the recent research evidence reported below, I have concluded there are other better options that offer the promise of symptom relief. It is not that the patches will do any harm, but the chances they may help is not promising in light of the recent research evidence.

Recent Studies that examine the impact of Nicotine as a Treatment for Parkinsons

Biomedicines. 2025 Jul 24;13(8):1814. Nicotine Therapy for Parkinson’s Disease: A Meta-Analysis of Randomized Controlled Trials

Abstract

Background: Epidemiological studies have reported an inverse association between smoking and Parkinson’s disease (PD) risk, prompting interest in nicotine as a potential therapeutic agent. The present meta-analysis evaluated the efficacy of nicotine therapy in improving motor symptoms and activities of daily living in patients with PD. 

Methods: PubMed, Embase, and Cochrane Library were systematically searched to identify randomized controlled trials (RCTs) assessing nicotine therapy in PD. Clinical RCTs administering interventions extending beyond 1 week and reporting motor or nonmotor outcomes were included. Random-effects models were used to analyze short-term (<6 months) and long-term (?6 months) outcomes by using standardized mean differences (SMDs). 

Results: This meta-analysis included five RCTs (346 participants). Nicotine therapy led to no significant improvement in motor outcomes in the short term (pooled SMD: -0.452, 95% confidence interval: -1.612 to 0.708) or long term (pooled SMD: 0.174, 95% confidence interval: -0.438 to 0.787). Considerable interstudy heterogeneity was noted. Furthermore, short-term nicotine therapy resulted in no significant improvement in daily functioning, cognition, or quality of life. 

Conclusions: This meta-analysis revealed a lack of compelling evidence suggesting that nicotine-based therapies improve motor or nonmotor outcomes in PD. The findings highlight a disconnect between epidemiological associations and clinical efficacy

******

J Parkinsons Dis. 2025 Nov;15(7):1121-1146. Proposed mechanisms of neuroprotection for nicotine in Parkinson’s disease

Abstract

The aim of this review is to summarize the current scientific evidence on nicotine in PD. We describe the large body of scientific articles that address the ways in which nicotine may affect Parkinson’s disease (PD).

Epidemiologic studies have shown that people who smoke have a lower risk of developing PD, and there are multiple potential explanations for why this may be the case. Because nicotine is one active ingredient in tobacco, many studies have used cellular or animal models of PD to try to determine how nicotine may reduce risk of PD or may be of benefit in established PD.

Many of these studies suggest that nicotine can prevent or reduce injury to dopaminergic neurons after exposure to toxic chemicals. However, many questions remain, and clinical trials in which patients with PD are treated with nicotine have largely not shown benefit to patients. Thus, neither smoking nor nicotine treatment are recommended for either prevention or treatment of PD at this time.

Robert Rodgers PhD
Founder 2004
Parkinsons Recovery ®
https://www.parkinsonsrecovery.com
robert@parkinsonsrecovery.com